SUN-LB318: Changes in Smell, Taste and Food Preferences in Colorectal Cancer Patients

Postma, EL; Boesveldt, Sanne; Kok, David; Kampman, Ellen

doi:10.1016/s0261-5614(17)30645-3

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, previous studies have shown that sensory variability in taste and smell may be driven by epigenetic markers in non-cancer cohorts (29,30). As sensory changes are typically transient and mostly recover to baseline levels after cessation of treatment, a modi able epigenetic mechanism such as DNAm is highly possible (31,32). In agreement, our results support the hypothesis DNAm in uences sensory factors to cause dysfunctions in olfactory measures, in chemotherapy-treated breast cancer patients.…”

Section: Discussionsupporting

confidence: 89%

Alterations to DNA methylation patterns induced by chemotherapy treatment are associated with negative impacts on the olfactory pathway

Ho,

Khng,

Benita

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Exposure to cytotoxic chemotherapy treatment may alter DNA methylation (DNAm) in breast cancer patients. Methods We performed DNAm analysis in 125 breast cancer patients with blood drawn before and after chemotherapy, using the Illumina MethylationEPIC array. DNAm changes of 588,798 individual CpGs and 41,222 promoters were evaluated using linear regression models adjusted for monocyte proportion. Gene set enrichment analyses (GSEA) were conducted to identify key Gene Ontology (GO) biological processes or KEGG pathways associated with chemotherapy. Results were validated in a separate cohort of breast cancer patients who were treated (n = 1,244) and not treated (n = 897) by chemotherapy (1,817 blood, 337 saliva). Results A total of 142 differentially methylated CpGs and 11 promoters were significantly associated with chemotherapy after multiple testing corrections in both the paired sample and single time point analyses. GSEA of 41,222 chemotherapy-associated promoters (pre-ranked by Z scores) revealed six suppressed biological processes that survived Bonferroni correction (GO:0007606, sensory perception of chemical stimulus; GO:0007608, sensory perception of smell; GO:0009593, detection of chemical stimulus; GO:0050906, detection of stimulus involved in sensory perception; GO:0050907, detection of chemical stimulus involved in sensory perception; and GO:0050911, detection of chemical stimulus involved in sensory perception of smell). The same six biological processes were significantly suppressed in the validation dataset. The KEGG pathway olfactory transduction (hsa04740) was also found to be significantly suppressed (uncorrected ppaired−samples=6.65e-5, psingle−timepoint−blood=1.01e-15 and p single−timepoint−saliva=3.10e-55). Conclusion The enrichment of imprinted genes within biological processes and pathways suggests a biological mechanism by which chemotherapy could affect the perception of smell.

show abstract

Section: Discussionsupporting

confidence: 89%

Alterations to DNA methylation patterns induced by chemotherapy treatment are associated with negative impacts on the olfactory pathway

Ho,

Khng,

Benita

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The presence of TDs can occur as acute side effects after chemotherapy [11] increasing according to the number of cycles received. Although these symptoms generally improve once treatment is completed [12], they may also persist for a long period after treatment is completed [13]. One of the most prevalent TDs, from the qualitative and quantitative point of view, is dysgeusia, which occurs in between 56% and 76% of patients receiving antineoplastic treatment [14].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: The CLINMIR Pilot Study

López-Plaza,

Álvarez-Mercado,

Arcos-Castellanos

et al. 2024

Nutrients

View full text Add to dashboard Cite

Taste disorders (TDs) are common among systemically treated cancer patients and negatively impact their nutritional status and quality of life. The novel food approved by the European Commission (EFSA), dried miracle berries (DMB), contains the natural taste-modifying protein miraculin. DMB, also available as a supplement, has emerged as a possible alternative treatment for TDs. The present study aimed to evaluate the efficacy and safety of habitual DMB consumption in malnourished cancer patients undergoing active treatment. An exploratory clinical trial was carried out in which 31 cancer patients were randomized into three arms [standard dose of DMB (150 mg DMB/tablet), high dose of DMB (300 mg DMB/tablet) or placebo (300 mg freeze-dried strawberry)] for three months. Patients consumed a DMB tablet or placebo daily before each main meal (breakfast, lunch, and dinner). Throughout the five main visits, electrochemical taste perception, nutritional status, dietary intake, quality of life and the fatty acid profile of erythrocytes were evaluated. Patients consuming a standard dose of DMB exhibited improved taste acuity over time (% change right/left side: −52.8 ± 38.5/−58.7 ± 69.2%) and salty taste perception (2.29 ± 1.25 vs. high dose: 2.17 ± 1.84 vs. placebo: 1.57 ± 1.51 points, p < 0.05). They also had higher energy intake (p = 0.075) and covered better energy expenditure (107 ± 19%). The quality of life evaluated by symptom scales improved in patients receiving the standard dose of DMB (constipation, p = 0.048). The levels of arachidonic (13.1 ± 1.8; 14.0 ± 2.8, 12.0 ± 2.0%; p = 0.004) and docosahexaenoic (4.4 ± 1.7; 4.1 ± 1.0; 3.9 ± 1.6%; p = 0.014) acids in erythrocytes increased over time after DMB intake. The standard dose of DMB increased fat-free mass vs. placebo (47.4 ± 9.3 vs. 44.1 ± 4.7 kg, p = 0.007). Importantly, habitual patients with DMB did not experience any adverse events, and metabolic parameters remained stable and within normal ranges. In conclusion, habitual consumption of a standard 150 mg dose of DMB improves electrochemical food perception, nutritional status (energy intake, fat quantity and quality, fat-free mass), and quality of life in malnourished cancer patients receiving antineoplastic treatment. Additionally, DMB consumption appears to be safe, with no changes in major biochemical parameters associated with health status. Clinical trial registered (NCT05486260).

show abstract

SUN-LB318: Changes in Smell, Taste and Food Preferences in Colorectal Cancer Patients

Cited by 2 publications

References 0 publications

Alterations to DNA methylation patterns induced by chemotherapy treatment are associated with negative impacts on the olfactory pathway

Alterations to DNA methylation patterns induced by chemotherapy treatment are associated with negative impacts on the olfactory pathway

Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: The CLINMIR Pilot Study

Contact Info

Product

Resources

About